BT Slingsby, MD, PhD, MPH, is Co-Founder and Director of Arialys Pharma. Dr. Slingsby is also Founder and Managing Director with Catalys Pacific where he leads the company creation efforts for the firm as is a physician-scientist and biotechnology entrepreneur. He has served as the founding CEO and subsequent Executive Chairman of Mineralys Therapeutics, Pathalys Pharma, Crystalys Therapeutics, Kirilys Therapeutics, Accelys Pharma, Aculys Pharma, Hepalys Pharma, and Renalys Pharma. Prior to Catalys Pacific, he founded and served as CEO and Executive Director of the Global Health Innovative Technology (GHIT) Fund – the world’s first public-private fund focused on the development of new medicines for low- and middle-income countries. Previously, he was an executive at Eisai Co. & Ltd following his time in academia. Dr. Slingsby graduated from Brown University with honors, earned his MPH and PhD from Kyoto University and the University of Tokyo, and received his MD with honors from the George Washington University. An author on over 50 peer-reviewed articles on medicine and public health, he formerly served as a Visiting Professor at Keio University, Kyoto University and Osaka University and Visiting Research Fellow at the University of Tokyo.